Actively Recruiting
Evaluation of Intravenous ATR 1072 for Adults With PRKAG2 Syndrome Assessing Safety, Pharmacokinetics, and Heart Effects
Led by Atrium Therapeutics · Updated on 2026-09-18
37
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating ATR 1072, an investigational antibody-oligonucleotide conjugate designed to reduce PRKAG2 gene expression, in adults with PRKAG2 Syndrome. This first-in-human, Phase 12, open-label, multicenter study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of multiple doses of ATR 1072. The study includes approximately 37 participants with PRKAG2 Syndrome confirmed by genetic testing and related clinical features. Participants receive ATR 1072 as an intravenous infusion every 6 weeks. The study has two parts Part A involves three sequential ascending dose cohorts with about 4 participants each receiving up to 8 doses over 48 weeks, followed by Part B which enrolls about 25 participants at the recommended dose to further evaluate safety and drug effects. After completing the 48-week treatment period, participants may enter a 42-week extension period and then a post-treatment follow-up lasting up to 18 weeks. During the study, participants undergo regular assessments including endomyocardial biopsies in Part A to measure drug concentration in cardiac tissue, as well as pharmacokinetic and pharmacodynamic evaluations. Researchers monitor treatment-emergent adverse events throughout approximately 48 weeks per participant. The study also evaluates changes in cardiac tissue and plasma drug levels over time to better understand ATR 1072s effects on PRKAG2 activity and heart disease measures.
CONDITIONS
Brief Title
ATR 1072 in Participants With PRKAG2 Syndrome
Research Team
P
Patient Recruitment Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here